A Healthcare Investor's Guide to Texas — What You Need to Know in 2026

Texas is the most active healthcare investment market in the southern United States and among the top three in the country. A combination of population growth, favourable regulation, and a strongly commercial insurance payer mix makes the state a compelling destination for investors evaluating healthcare businesses across the risk-return spectrum. This guide provides a structured overview of the opportunity, the landscape, and the diligence framework that sophisticated investors use when entering Texas healthcare.

Why Texas for Healthcare Investment

Texas offers a uniquely favourable investment environment for healthcare operators and their capital partners:

• No state income tax. Returns generated by Texas-based healthcare businesses benefit from the absence of state-level income tax on both corporate earnings and personal distributions — a structural advantage relative to California, New York, and other major healthcare markets.
• Population growth. The Dallas–Fort Worth metro adds approximately 170,000 residents per year. Healthcare demand is directly correlated with population density, and DFW is building the patient base to support significant new capacity.
• Commercial insurance penetration. Texas has a higher-than-average proportion of commercially insured patients relative to Medicaid-heavy markets, supporting revenue yields that justify the capital investment required for freestanding ER and ambulatory healthcare businesses.
• Permissive regulatory framework. Texas pioneered the freestanding ER model and maintains a relatively operator-friendly regulatory environment through DSHS, compared to certificate-of-need (CON) states where new facility development is constrained by bureaucratic approval processes.

Investment Asset Classes

Texas healthcare investment opportunities cluster around four primary asset classes, each with a distinct risk-return profile:

• Freestanding emergency rooms (FSERs). The highest revenue-per-visit asset class in Texas ambulatory healthcare. Typical revenue ranges from $3M to $12M per site depending on volume and payer mix. EBITDA margins of 20–35% are achievable at maturity. Requires the most intensive diligence due to DSHS licensing, physician credentialing, and payer contracting complexity.
• Medical spas. Lower capital intensity than FSERs, faster to profitability, and highly scalable with a strong brand. Revenue per location typically ranges from $1M to $4M. Attractive for investors seeking a portfolio of complementary healthcare lifestyle assets.
• Urgent care centres. Well-understood operating model with established benchmarks. More sensitive to competition from retail health clinics (CVS MinuteClinic, Amazon Clinic) than FSERs, which occupy a higher-acuity niche.
• Ambulatory surgical centres (ASCs). High-value, physician-partnership-dependent assets. Revenue and margin are stronger than most ambulatory categories but require complex payer contracting and a committed physician partnership base to maintain volume.

Regulatory Landscape

Texas healthcare regulation is primarily administered by the Texas Department of State Health Services (DSHS) for facility licensing and the Texas Medical Board (TMB) for physician and clinical staff credentialing. Key regulatory considerations for investors include:

• DSHS freestanding ER licence must be current, with no outstanding deficiency citations
• The Texas Corporate Practice of Medicine doctrine limits non-physician ownership of clinical entities — most structures use a management services organisation (MSO) to separate investor ownership from clinical operations
• Medicare and Medicaid enrolment for FSERs does not follow hospital-based ER billing rules — understanding the reimbursement delta is essential for accurate financial modelling
• Texas surprise billing law (HB 2balance) affects out-of-network reimbursement for FSERs — confirm the target asset's payer contract status before close

Due Diligence Checklist

A healthcare-specific diligence process should cover, at minimum:

• DSHS licence history, inspection reports, and any outstanding citations
• Payer contracts by insurer, contracted rates, and contract expiry dates
• Net collection rate trended over 24 months (target: >96%)
• Physician and nursing staff tenure and turnover rate
• Revenue cycle management provider and denial rate by payer
• Three years of GAAP-audited or reviewed financial statements
• Patient volume by month and year for trend analysis
• Accounts receivable ageing (target: <15% over 90 days)
• Malpractice claims history and current coverage limits
• Lease terms and landlord assignment consent provisions

Valuation Benchmarks

Texas FSER valuations have typically ranged from 5× to 9× EBITDA in recent transactions, with variance driven by payer mix quality, physician contract terms, lease length, and volume growth trajectory. Medspas transact at a wider range — 3× to 7× EBITDA — reflecting the higher personal-brand concentration risk in owner-operated single-site businesses.

Investors should normalise EBITDA carefully: physician owner compensation, non-recurring start-up costs, and below-market rent are common adjustments that materially affect the accurate valuation baseline.

How Focus Supports Investors

Focus works with healthcare investors at every stage — from pre-acquisition diligence and financial modelling through to post-acquisition operational improvement and scale. The Focus Four-Layer ER Growth System is designed to de-risk and accelerate the value creation phase after acquisition by deploying clinical, financial, data, and marketing capabilities in a coordinated programme.

For investors evaluating the Texas healthcare market, Focus provides market intelligence, introductions to qualified operators, and independent operational assessments that support investment committee decision-making.

Learn more about Focus's investor relations or speak directly with the team.